Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

| April 6, 2015 | 0 Comments

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

Read More:
Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Tags: , , , , , , , , , ,

Category: Recent News

About the Author ()

Leave a Reply